News Breaks |
|
|
| November 13, 2012 |
| 16:41 EDT |  | EW, MDT | Appeals ruling a significant legal victory for Edwards, says Wells Fargo
Wells Fargo said it views today's appeals court ruling as a significant legal victory for Edwards Lifesciences (EW), noting it's the third favorable court ruling for Edwards in its litigation with Medtronic's (MDT) CoreValve. Wells estimates the upside to Edwards Lifesciences from the litigation could be about $486M after tax, or $4.11 per share. The firm continues to expect both companies to negotiate a settlement which would allow Medtronic to enter the U.S. market once CoreValve receives approval towards the end of 2014. Wells Fargo has an Outperform rating on Edwards Lifesciences. |
|
|
News For EW;MDT From The Last 14 Days Check below for free stories on EW;MDT the last two weeks. |
|
|
| May 23, 2013 |
| 05:40 EDT |  | MDT | Medtronic CoreValue system gains CE mark for transcatheter VIV procedures
 Subscribe for More Information |
|
| 05:38 EDT | | MDT | Medtronic's In.Pact Falcon yields positive outcomes in small coronary arteries
Subscribe for More Information |
|
| May 22, 2013 |
| 07:48 EDT |  | MDT | FDA Orthopaedic and Rehabilitation Devices Panel to hold a meeting
Subscribe for More Information |
|
| May 21, 2013 |
| 13:02 EDT | | MDT | Medtronic announces CE Mark for CapSureFix Novus
Medtronic announced CE Mark and launch of its CapSureFix Novus 5076 Lead, which is now approved in the EU for use in an MRI environment when paired with a Medtronic MR-Conditional pacemaker. The lead has not been approved for that use in the U.S. |
|
| 11:38 EDT |  | MDT | High option volume stocks: KOS MWE HGG SOL MDT
|
|
| 10:46 EDT | | EW | Edwards Lifesciences announces positive outcomes from study of SAPIEN XT
Subscribe for More Information |
|
| 09:25 EDT | | MDT | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 07:19 EDT |  | MDT | Medtronic sees FY14 EPS $3.80-$3.85, consensus $3.84
Sees FY14 revenue growth up 3%-4% on a constant currency basis. |
|
| 07:17 EDT | | MDT | Medtronic reports Q4 EPS $1.10, consensus $1.03
Subscribe for More Information |
|
| 05:54 EDT | | MDT | Medtronic announces primary results from Global Symplicity Registry
Subscribe for More Information |
| |
| 05:51 EDT | | MDT | Medtronic CoreValue ADVANCE study shows low mortality rates
Subscribe for More Information |
|
| May 20, 2013 |
| 15:22 EDT | | MDT | Notable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Home Depot (HD), consensus 77c; Medtronic (MDT), consensus $1.03; The TJX Companies (TJX), consensus 62c; AutoZone (AZO), consensus $7.23; Best Buy (BBY), consensus 25c; Dick's Sporting Goods (DKS), consensus 48c; Tidewater (TDW), consensus 61c; Saks (SKS), consensus 19c; Rexnord (RXN), consensus 31c; Monro Muffler Brake (MNRO), consensus 25c. |
|
| 09:41 EDT | | MDT | Supreme Court agrees to hear Medtronic-Boston Scientific patent case
Reported by SCOTUSblog live blog of court orders and opinions. |
|
| 07:11 EDT | | MDT | Medtronic receives CE mark for 'export advance' aspiration catheter
Subscribe for More Information |
|
| May 16, 2013 |
| 13:32 EDT | | MDT | Medtronic volatility flat into Q4 and outlook
Subscribe for More Information |
|
| 10:03 EDT |  | MDT | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 06:32 EDT | | MDT | Medtronic downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information |
|
| May 15, 2013 |
| 07:17 EDT | | EW | Edwards Lifesciences share repurchases positive, says Wells Fargo
Subscribe for More Information |
|
| May 14, 2013 |
| 09:27 EDT | | EW | Edwards Lifesciences CEO to purchase $5M of company stock
The company announced that Michael A. Mussallem, Edwards' chairman and CEO, will make a $5M cash purchase of newly issued shares of Edwards common stock. |
|
| 09:26 EDT | | EW | Edwards Lifesciences announces new $750M share repurchase program
Edwards Lifesciences announced that its board has authorized a new share repurchase program to acquire up to an additional $750M of the company's outstanding common shares. As of March 31, Edwards had approximately $140M remaining of its current $500M share repurchase program, which was authorized in September 2011. Edwards expects to utilize the remainder of the $500M repurchase authorization during Q2. |
| |
|
|
|
|
